Loading...
| A14999 | Pages: 241 | Dec 2021 | 198 Views | | |
| Author(s) : Divyani Talekar, Shilpi Chowdhury , Onkar Sumant | Tables: 119 | Charts: 44 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Artificial Coma/medically Induced Coma Market
Request Now !The global artificial coma/medically induced coma market size was valued at $640.17 Million in 2020, and is projected to reach $868.63 Million by 2030, registering a CAGR of 3.1%. Medically induced coma is also known as drug-induced coma. It is induced in patients in case of traumatic brain injury, where there is a need to cure the infection. At that time doctors use certain drugs to induce coma. It is a state of unconsciousness that the body doesn’t feel pain. It is an effective shutdown of the brain activity during surgical procedure of trauma. Shutting down the function of the brain gives time to heal. In addition, there are numerous reasons to induce coma in patients with critical health issues, which includes brain infection such as meningitis and rabies.
The COVID-19 outbreak is anticipated to have a slightly positive impact on growth of the global artificial coma/medically induced coma market owing to the increasing used anesthetic drugs for the Covid-19 patients those were at high risk of brain infection. Many Covid-19 patients were put on artificial coma/medically induced coma to save the patients from internal brain swelling. The Covid-19 patient usually take 10 days to 3 months to get out of the medically induced coma.
Meningitis is an inflammation caused to brain and spinal cord. It causes swelling of the brain. Meningitis includes some types such as bacterial meningitis, viral meningitis, and fungal meningitis. In case of bacterial meningitis, bacteria enter the blood stream and travel to the brain and cause bacterial meningitis. It can be life threatening, if not treated at the right time. Therefore, it requires a surgical procedure to cure the infection. Artificial coma is an option to reduce the pain during surgery and the patient is unaware about this.
Get more information on this report : Request Sample Pages
Anesthetics are used to induce coma, they are propofol and barbiturate. Propofol is a sedative agent that can be used for the induction of general anesthesia. Propofol slows down the function of the brain. It is used to sedate patients who are under critical care and require a mechanical ventilator in intensive care unit. Moreover, barbiturate is also an anesthetic drug and also called as central nervous system depressant. It is available under the brand names such as butabarbital, pentobarbital, phenobarbital and others.
Growth of the global artificial coma/medically induced coma market is majorly driven by increase in prevalence of traumatic brain injury; increase in various types of brain infection such as meningitis; increase in cases of wound exposure that causes harm to the brain. Therefore, these aforementioned factors increase the use of anesthetics to induce coma, which drives the growth of the artificial coma/medically induced coma market. According to the American Heart Association Stroke Statistical Update in 2019, there were 101.5 million cases of stroke. Whereas, out of this an ischemic stroke cases was 77.2 million, intracerebral hemorrhage cases were 20.7 million. Thus, rise in burden of stroke is increasing the number of surgeries.
Traumatic brain injury is the main cause of death and disability, there were an approximately 500-800 new cases of traumatic brain injury each year in the U.S and New Zealand. These aforementioned factors led to surge in usage of anesthetics to induce coma during treatment of traumatic brain injury and are anticipated to drive the growth of the artificial coma/medically induced coma market. Furthermore, rise in geriatric population leads to surge in cardiovascular and chronic diseases, these factors fuel the growth of the artificial coma/medically induced market. For instance, in August 2019, AstraZeneca launched propofol injectable, which is used for the maintenance of general anesthesia for mechanically ventilated patients in intensive care unit. In May 2020, Hikma Pharmaceuticals announced the launch of propofol injectable emulsion for maintenance of sedation and anesthesia. Thus, increase in usage of anesthetics during surgical procedure fuels the market growth.
The presence of key players such as neon laboratories, Claris Life Sciences, Teva Pharmaceuticals, and Piramal Healthcare, and rise in initiatives of key players in the field of new drug innovation drives the growth of the market.
The COVID-19 outbreak is anticipated to have a positive impact on the global artificial coma/medically induced coma market. At the starting of July 2020, a few cases have been reported brain infection of meningitis with COVID-19 at the same time. Therefore, anesthetics play an important role during treatment, these aforementioned factors are anticipated to drive the artificial coma/medically induced coma market during the forecast period.
However, the side effects associated with use of anesthetics for induced coma hinder the market growth during the forecast period.
The global artificial coma/medically induced coma market is segmented on the basis of drug type, application, distribution channel and region. By drug type, the market is categorized into propofol and barbiturate.
On the basis of application, it is divided into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others.
On the basis of distribution channel, it is divided into hospital pharmacies, and drug stores and retail pharmacies.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).
Depending on drug type, the propofol segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical industry, increase in number of surgeries, and surge in production of new drug launch. However, the barbiturate segment is expected to witness considerable growth during the forecast period, owing to increase in number of traumatic brain injury and increase in number of key players for development of anesthetics drug.
Get more information on this report : Request Sample Pages
By application, the stroke segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of stroke. However, the status epilepticus segment is expected to witness considerable growth during the forecast period, due to increase in number of COVID-19 cases causing meningitis, rise in number of surgical procedures, and development of advanced drugs to complete the needs in healthcare.
On the basis of distribution channel, the hospital pharmacies segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to large number of key players offering various types of anesthetic drugs, increase in demand for safe care, and advancement in R&D activities for drug discovery. However, the drug stores & retail pharmacies segment is expected to witness considerable growth during the forecast period, owing to increase in cerebrovascular diseases, which can lead to stroke, or even death.
Get more information on this report : Request Sample Pages
North America garnered a major share in the artificial coma/medically induced coma market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of traumatic brain injury, presence of key players, development of the healthcare sector, and presence of new innovative medications in the region. However, Asia-Pacific is expected to register the highest CAGR of 3.6% from 2021 to 2030, owing to increase in prevalence of geriatric population, and development of healthcare infrastructure.
The key players operating in the global artificial coma/medically induced coma market include Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr.Reddy's Laboratories, Fresenious SE& CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.
Get more information on this report : Request Sample Pages
Key Benefits for Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Escalating demand for the management of pain from geriatric population
3.5.1.2.Increase in number of emergency surgeries
3.5.1.3.Increase in number of drug launch and approvals
3.5.1.4.Rising prevalence of cancer
3.5.2.Restraints
3.5.2.1.Risk associated with the use of anesthetics in pediatric patients and pregnant women
3.5.2.2.Side effects associated with anesthetics
3.5.3.Opportunity
3.5.3.1.Rise in heavy investment in healthcare sector
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the artificial coma/medically induced coma market
CHAPTER 4:ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Propofol
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Barbiturate
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
CHAPTER 5:ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Status Epilepticus
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Stroke
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Traumatic Brain Injury
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Brain Infections
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Drug Overdose
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Others
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
CHAPTER 6:ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug Stores & Retail Pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America artificial coma/medically induced coma market, by type
7.2.3.North America artificial coma/medically induced coma market, by Application
7.2.4.North America artificial coma/medically induced coma market, by distribution channel
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. artificial coma/medically induced coma market, by type
7.2.5.1.2.U.S. artificial coma/medically induced coma market, by application
7.2.5.1.3.U.S. artificial coma/medically induced coma market, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada artificial coma/medically induced coma market, by type
7.2.5.2.2.Canada artificial coma/medically induced coma market, by application
7.2.5.2.3.Canada artificial coma/medically induced coma market, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico artificial coma/medically induced coma market, by type
7.2.5.3.2.Mexico artificial coma/medically induced coma market, by application
7.2.5.3.3.Mexico artificial coma/medically induced coma market, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe artificial coma/medically induced coma market, by type
7.3.3.Europe artificial coma/medically induced coma market, by application
7.3.4.Europe artificial coma/medically induced coma market, by distribution channel
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany artificial coma/medically induced coma market, by type
7.3.5.1.2.Germany artificial coma/medically induced coma market, by application
7.3.5.1.3.Germany artificial coma/medically induced coma market, by distribution channel
7.3.5.2.France
7.3.5.2.1.France artificial coma/medically induced coma market, by type
7.3.5.2.2.France artificial coma/medically induced coma market, by application
7.3.5.2.3.France artificial coma/medically induced coma market, by distribution channel
7.3.5.3.UK
7.3.5.3.1.UK artificial coma/medically induced coma market, by type
7.3.5.3.2.UK artificial coma/medically induced coma market, by application
7.3.5.3.3.UK artificial coma/medically induced coma market, by distribution channel
The UK artificial coma/medically induced coma market was valued at $31.19 million in 2020, and is projected to reach $42.95 million by 2030, registering a CAGR of 3.2%. The hospital pharmacies was the highest revenue contributor with $20.60 million in 2020, and is estimated to reach $28.87 million by 2030, registering a CAGR of 3.4%.
7.3.5.4.Italy
7.3.5.4.1.Italy artificial coma/medically induced coma market, by type
7.3.5.4.2.Italy artificial coma/medically induced coma market, by application
7.3.5.4.3.Italy artificial coma/medically induced COMA market, by distribution channel
7.3.5.5.Spain
7.3.5.5.1.Spain artificial coma/medically induced coma market, by type
7.3.5.5.2.Spain artificial coma/medically induced coma market, by application
7.3.5.5.3.Spain artificial coma/medically induced coma market, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe artificial coma/medically induced coma market, by type
7.3.5.6.2.Rest of Europe artificial coma/medically induced coma market, by application
7.3.5.6.3.Rest of Europe artificial coma/medically induced coma market, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific artificial coma/medically induced coma market, by type
7.4.3.Asia-Pacific artificial coma/medically induced coma market, by Application
7.4.4.Asia-Pacific artificial coma/medically induced coma market, by distribution channel
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan artificial coma/medically induced coma market, by type
7.4.5.1.2.Japan artificial coma/medically induced coma market, by application
7.4.5.1.3.Japan artificial coma/medically induced coma market, by distribution channel
7.4.5.2.China
7.4.5.2.1.China artificial coma/medically induced coma market, by type
7.4.5.2.2.China artificial coma/medically induced coma market, by application
7.4.5.2.3.China artificial coma/medically induced coma market, by distribution channel
7.4.5.3.Australia
7.4.5.3.1.Australia artificial coma/medically induced coma market, by type
7.4.5.3.2.Australia artificial coma/medically induced coma market, by application
7.4.5.3.3.Australia artificial coma/medically induced coma market, by distribution channel
7.4.5.4.India
7.4.5.4.1.India artificial coma/medically induced coma market, by type
7.4.5.4.2.India artificial coma/medically induced coma market, by application
7.4.5.4.3.India artificial coma/medically induced coma market, by distribution channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea artificial coma/medically induced coma market, by type
7.4.5.5.2.South Korea artificial coma/medically induced coma market, by application
7.4.5.5.3.South Korea artificial coma/medically induced coma market, by distribution channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific artificial coma/medically induced coma market, by type
7.4.5.6.2.Rest of Asia-Pacific artificial coma/medically induced coma market, by application
7.4.5.6.3.Rest of Asia-Pacific artificial coma/medically induced coma market, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA artificial coma/medically induced coma market, by type
7.5.3.LAMEA artificial coma/medically induced coma market, by application
7.5.4.LAMEA artificial coma/medically induced coma market, by distribution channel
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil artificial coma/medically induced coma market, by type
7.5.5.1.2.Brazil artificial coma/medically induced coma market, by application
7.5.5.1.3.Brazil artificial coma/medically induced coma market, by distribution channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia artificial coma/medically induced coma market, by type
7.5.5.2.2.Saudi Arabia artificial coma/medically induced coma market, by application
7.5.5.2.3.Saudi Arabia artificial coma/medically induced coma market, by distribution channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa artificial coma/medically induced coma market, by type
7.5.5.3.2.South Africa artificial coma/medically induced coma market, by application
7.5.5.3.3.South Africa artificial coma/medically induced coma market, by distribution channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA artificial coma/medically induced coma market, by type
7.5.5.4.2.Rest of LAMEA artificial coma/medically induced coma market, by application
7.5.5.4.3.Rest of LAMEA artificial coma/medically induced coma market, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.ASTRAZENECA PLC
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.B.BRAUN MELSUNGEN AG
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.BAXTER INTERNATIONAL INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product Portfolio
8.3.5.Business performance
8.4.DR. REDDY’S LABORATORY
8.4.1.Company overview
8.5.FRESENIUS SE & CO KGAA
8.5.1.Company Overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.HIKMA PHARMACEUTICALS
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.PFIZER INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.PIRAMAL GROUP
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.VIATRIS INC. (MYLAN N.V)
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 02.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR PROPOFOL, BY REGION, 2020–2030 ($MILLION)
TABLE 03.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR BARBITURATE, BY REGION, 2020–2030 ($MILLION)
TABLE 04.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 05.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STATUS EPILEPTICUS , BY REGION, 2020–2030 ($MILLION)
TABLE 06.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STROKE, BY REGION, 2020–2030 ($MILLION)
TABLE 07.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR TRAUMATIC BRAIN INJURY, BY REGION, 2020–2030 ($MILLION)
TABLE 08.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR BRAIN INFECTION, BY REGION, 2020–2030 ($MILLION)
TABLE 09.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG OVEREDOSE, 2020–2030 ($MILLION)
TABLE 10.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 11.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 12.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 13.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 14.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15.NORTH AMERICA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 16.NORTH AMERICAARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICAARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICAARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 19.U.S. ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 20.U.S. ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 21.U.S. ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTIO CHANNEL, 2020-2030 ($MILLION)
TABLE 22.CANADA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 23.CANADA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 24.CANADA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 25.MEXICO ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 26.MEXICO ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 27.MEXICO ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION HANNEL, 2020-2030 ($MILLION)
TABLE 28.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 30.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 31.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 32.GERMANY ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 33.GERMANY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 34.GERMANY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTON CHANNEL, 2020-2030 ($MILLION)
TABLE 35.FRANCE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 36.FRANCE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 37.FRANCE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 38.UK ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 39.UK ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 40.UK ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 41.ITALY ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 42.ITALY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 43.ITALY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 44.SPAIN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 45.SPAIN ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 46.SPAIN ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 47.REST OF EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 48.REST OF EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 49.REST OF EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 50.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 51.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 52.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 54.JAPAN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 55.JAPAN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 56.JAPAN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 57.CHINA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 58.CHINA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 59.CHINA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 60.AUSTRALIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 61.AUSTRALIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 62.AUSTRALIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 63.INDIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 64.INDIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 65.SOUTH KOREA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 66.INDIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 70.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 71.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 72.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 73.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 74.BRAZIL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 75.BRAZIL ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 76.BRAZIL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 77.SAUDI ARABIA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 78.SAUDI ARABIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 79.SAUDI ARABIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 80.SOUTH AFRICA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 81.SOUTH AFRICA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 82.SOUTH AFRICA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 83.REST OF LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 84.REST OF LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 85.REST OF LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 86.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 87.ASTRAZENECA: OPERATING SEGMENTS
TABLE 88.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 89.ASTRAZENCA:KEY STRATEGIES & DEVELOPMENTS
TABLE 90.B. BRAUN:: COMPANY SNAPSHOT
TABLE 91.B. BRAUN :OPERATING SEGMENTS
TABLE 92.B. BRAUN: PRODUCT PORTFOLIO
TABLE 93.BAXTER: COMPANY SNAPSHOT
TABLE 94.BAXTER:OPREATING SEGMENTS
TABLE 95.BAXTER: PRODUCT PORTFOLIO
TABLE 96.REDDY’S:COMPANY SNAPSHOT
TABLE 97.REDDY’S: OPERATING SEGMENTS
TABLE 98.REDDY’S: PRODUCT PORTFOLIO
TABLE 99.REDDY’S : KEY STRATEGIES & DEVELOPMENTS
TABLE 100.FRESENIUS : COMPANY SNAPSHOT
TABLE 101.FRESENIUS: OPERATING SEGMENTS
TABLE 102.FRESENIUS: PRODUCT PORTFOLIO
TABLE 103.FRESENIUS : KEY STRATEGIES & DEVELOPMENTS
TABLE 104.HIKMA:COMPANY SNAPSHOT
TABLE 105.HIKMA:OPERATING SEGMENTS
TABLE 106.HIKMA: PRODUCT PORTFOLIO
TABLE 107.HIKMA: KEY STATEGIES & DEVELOPMENTS
TABLE 108.PFIZER: COMPANY SNAPSHOT
TABLE 109.PFIZER: OPERATING SEGMENTS
TABLE 110.PFIZER: PRODUCT PORTFOLIO
TABLE 111.PIRAMAL: COMPANY SNAPSHOT
TABLE 112.PIRAMAL: OPERATING SEGMENTS
TABLE 113.PIRAMAL: PRODUCT PORTFOLIO
TABLE 114.TEVA: COMPANY SNAPSHOT
TABLE 115.TEVA: OPERATING SEGMENTS
TABLE 116.TEVA: PRODUCT PORTFOLIO
TABLE 117.VIATRIS : COMPANY SNAPSHOT
TABLE 118.VIATRIS INC.: OPERATING SEGMENTS
TABLE 119.VIATRIS INC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2020
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR PROPOFOL, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR BARBITURATE, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STATUS EPILEPTICUS, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STROKE, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR TRAUMATIC BRAIN INJURY, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR BRAIN INFECTIONS, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG OVERDOSE, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR OTHERS, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2020–2030 (%)
FIGURE 23.ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
FIGURE 24.ASTRAZENECA: REVENUE SHARE BY REGION (%)
FIGURE 25.B. BRAUN: NET SALES, 2018-2020 ($MILLION)
FIGURE 26.BAXTER: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28.BAXTER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.REDDY’S: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.REDDY’S: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.FRESENIUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.FRESENIUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34.HIKMAN: NET SALES, 2018-2020 ($MILLION)
FIGURE 35.HIKMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.PIRAMAL: NET SALES, 2018-2020 ($MILLION)
FIGURE 39.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.TEVA: REVENUE SHARE BY SEGMENT 2020 (%)
FIGURE 41.TEVA: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 42.VIATRIS : NET SALES, 2018–2020 ($MILLION)
FIGURE 43.VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.VIATRIS: REVENUE SHARE BY REGION, 2020(%)
Increasing prevalence of stroke, rising geriatric population and increase in incidences of brain injuries, advancements in drug discovery are all attributed for growth of the artificial coma/medically induced coma market. Greater consumer awareness of and demand for preventive healthcare services, escalating demand for healthcare services from overall population and new advancements are predicted to broaden anesthetics drug’s clinical applications and increase the number of surgeries conducted.
In addition, rising surgeries related to stroke, brain infections, traumatic brain injury, status epilepticus and other disorders are expected to drive the market. Furthermore, the emergency use of propofol during surgeries contributes toward the growth of the market.
The market gains interest of healthcare companies, owing to focus on preventive facilities provide to the patients who undergoing critical surgeries, which are more complex than other health conditions. This leads to increase in utilization for anesthetics to inducing coma, thus is a great opportunity for further propelling the growth of the market.
North America is expected to witness highest growth, in terms of revenue, owing to rise in geriatric population, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to increase in incidences of sport injuries, and unmet needs for advanced drug innovation and. However, side effects associated with the use of anesthetics and stringent government policies may restrain the market growth during the forecast period.
A. The total market value of artificial coma/medically Induced coma market is $ 640.17 million in 2020.
A. The forecast period for artificial coma/medically Induced coma market is 2021 to 2030
A. The market value of artificial coma/medically Induced coma market in 2021 is $868.63 millon.
A. The base year is 2020 in artificial coma/medically Induced coma market
A. Top companies such as Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr.Reddy's Laboratories, Fresenius SE & CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.held a high market position in 2020.
A. Based on drug type, Propofol segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due new product launch and thus is expected to drive the segment
A. Increase in development of advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.
A. North America is projected to account for a major share of 48.5% the global artificial coma/medically induced coma market during the forecast period. U.S. dominated the North America rise in investments for new product launch in the R & D sector due to presence of key players across the country.
A. Artificial coma/medically Induced coma is a state of unconsiousness. It effectively shut down brain's activity.
A. Artificial coma/medically Induced coma drugs are used to induced coma during treatment of disorders such as stroke, traumatic brain injury, brain infections and status epilepticus.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
